Group I | Group II | Group III | Group IV | Group V | Group VI | |
---|---|---|---|---|---|---|
negative control | cisplatin ‘CDDP’-treated | cisplatin + rBMSCs-treated | cisplatin + hADSCs-treated (n = 20) | cisplatin + hAFSCs-treated | cisplatin + DMEM culture media-treated | |
Active injury | ||||||
Day 4 | 0.0 (0.0–0.0) | 7.0 (7.0–7.0)a | 3.0 (2.0–3.0)ab | 3.0 (2.0–3.0)ab | 3.0 (2.0–3.0)ab | 6.0 (6.0–7.0)abcde |
Day 7 | 0.0 (0.0–0.0) | 6.0 (6.0–6.0)a | 3.0 (3.0–3.0)ab | 3.0 (2.0–3.0)ab | 3.0 (2.0–3.0)ab | 6.0 (6.0–6.0)abcde |
Day 11 | 0.0 (0.0–0.0) | 4.0 (4.0–4.0)a | 1.0 (1.0–1.0)ab | 1.0 (1.0–1.0)ab | 1.0 (1.0–1.0)ab | 6.0 (5.0–6.0)abcde |
Day 30 | 0.0 (0.0–0.0) | 4.0 (4.0–4.0)a | 1.0 (0.0–1.0)b | 1.0 (1.0–1.0)b | 1.0 (1.0–1.0)ab | 3.0 (3.0–3.0)abcde |
Regeneration | ||||||
Day 4 | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 4.0 (4.0–5.0)ab | 4.0 (4.0–5.0)ab | 4.0 (3.0–5.0)ab | 0.0 (0.0–0.0)cde |
Day 7 | 0.0 (0.0–0.0) | 0.0 (0.0–0.0) | 6.0 (5.0–6.0)ab | 6.0 (6.0–6.0)ab | 7.0 (6.0–7.0)abc | 0.0 (0.0–0.0)cde |
Day 11 | 0.0 (0.0–0.0) | 1.0 (1.0–2.0)a | 8.0 (7.0–8.0)ab | 8.0 (7.0–9.0)ab | 8.0 (8.0–8.0)ab | 1.0 (1.0–2.0)acde |
Day 30 | 0.0 (0.0–0.0) | 3.0 (3.0–3.0)a | 9.0 (8.0–9.0)ab | 8.0 (7.0–9.0)ab | 8.0 (7.0–9.0)ab | 3.0 (3.0–3.0)acde |
Chronicity | ||||||
Day 4 | 0.0 (0.0–0.0) | 3.0 (3.0–3.0)a | 2.0 (1.0–2.0)ab | 2.0 (1.0–2.0)ab | 2.0 (2.0–2.0)ab | 3.0 (3.0–3.0)acde |
Day 7 | 0.0 (0.0–0.0) | 4.0 (4.0–4.0)a | 2.0 (2.0–3.0)ab | 2.0 (2.0–2.0)ab | 2.0 (2.0–2.0)ab | 4.0 (4.0–5.0)acde |
Day 11 | 0.0 (0.0–0.0) | 5.0 (5.0–5.0)a | 2.0 (2.0–2.0)ab | 2.0 (2.0–2.0)ab | 2.0 (2.0–2.0)ab | 5.0 (5.0–5.0)acde |
Day 30 | 0.0 (0.0–0.0) | 3.0 (3.0–4.0)a | 2.0 (2.0–2.0)ab | 2.0 (2.0–2.0)ab | 2.0 (2.0–2.0)ab | 3.0 (3.0–3.0)acde |